Calprotectina fecal como marcador diferencial entre patología gastrointestinal orgánica y funcional / No disponible

ABSTRACT

Introduction: there is growing evidence showing the importanceof the fecal calprotectin assay in differentiating organic fromfunctional gastrointestinal disease. It is a simple, non-invasive biomarkerthat is especially useful in children, who may require generalanesthesia for colonoscopy. The aim of this study was to assessthe use and sensitivity of fecal calprotectin (FCP) in pediatricpatients with signs and symptoms of IBD to avoid unnecessary invasivetechniques and to distinguish between organic and functionalgastrointestinal pathology.Material and methods: a single stool sample was collectedfrom 47 children (mean age: 10.1 years) referred for non-specificgastrointestinal symptoms suggestive of organicity. On the basisof clinical criteria 13 children had functional bowel disorders and34 had organic gastrointestinal disease, 15 with IBD and 19 withother organic (non-IBD) gastrointestinal conditions. Thirty healthychildren were included as controls. Calprotectin concentrationswere measured by enzyme immunoassay.Results: children with IBD had FCP levels [median (interquartilerange); 1,219 μg/g (322-2,967 μg/g)] higher than children withfunctional gastrointestinal disease [20 μg/g (16-25 μg/g); p <0.0001], those with organic non-IBD disease [113 μg/g (36-193μg/g); p = 0.002], and healthy children [25 μg/g (19.2-32.5 μg/g);p < 0.0001]. Fecal calprotectin concentration also was significantlyhigher in children with organic (non-IBD) disease as compared tocontrols (p = 0.004) and children with functional pathology (p =0.002). FCP levels were similar in controls and children with functionalgastrointestinal disease (p = 0.264).Discussion: CPF is a sensitive, but not disease-specific, markerto identify patients with IBD who should undergo diagnosticcolonoscopy, and to avoid unnecessary invasive procedures in patientswith functional gastrointestinal disorders (AU)